Table 3 Univariate Cox proportional hazards models with left truncation assessing the impact of lenalidomide treatment and baseline covariates on AML progression and mortality

From: Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

Variable

AML progression

Mortality

 

HR (95% CI)

P-value

HR (95% CI)

P-value

Lenalidomide-treated vs untreated cohort

1.306 (0.727–2.346)

0.372

0.949 (0.686–1.313)

0.753

Age, years

0.993 (0.975–1.011)

0.418

1.040 (1.027–1.053)

<0.001

Gender (female vs male)

0.700 (0.447–1.095)

0.118

0.534 (0.405–0.703)

<0.001

Cytogenetic complexity (del(5q) plus>1 abnormality vs isolated)

4.626 (2.354–9.090)

<0.001

2.358 (1.409–3.946)

0.001

Cytogenetic complexity (del(5q) plus 1 abnormality vs isolated)

1.336 (0.767–2.327)

0.306

0.993 (0.689–1.431)

0.972

Bone marrow blast count (5–10% vs<5%)

1.626 (0.871–3.030)

0.127

1.332 (0.883–2.008)

0.173

RBC transfusion burden, units/8 weeks

1.106 (1.032–1.186)

0.005

1.093 (1.050–1.139)

< 0.001

Hemoglobin level, g/dl

0.891 (0.773–1.026)

0.109

0.895 (0.818–0.980)

0.016

Anemia

1.466 (0.734–2.924)

0.279

1.695 (1.058–2.717)

0.028

Platelet count, × 109/l

0.999 (0.998–1.001)

0.344

0.999 (0.998–1.000)

0.004

Thrombocytopenia

1.011 (0.464–2.203)

0.979

2.006 (1.377–2.924)

<0.001

Neutrophil count, × 106/l

1.000 (1.000–1.000)

0.350

1.000 (1.000–1.000)

0.163

Neutropenia

0.837 (0.533–1.314)

0.441

0.932 (0.705–1.233)

0.621

IPSS risk (Int-1 vs Low)

1.586 (0.967–2.601)

0.068

1.069 (0.797–1.433)

0.657

  1. Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; HR, hazard ratio; Int, Intermediate; IPSS, International Prognostic Scoring System; RBC, red blood cell.
Back to article page